FDA spurns Min­er­va’s schiz­o­phre­nia drug in RTF, send­ing share price in­to tail­spin

The writ­ing was on the wall.

The FDA spelled out its qualms with Min­er­va Neu­ro­sciences’ schiz­o­phre­nia drug can­di­date rolu­peri­done in 2020. Nev­er­the­less, the biotech pushed for­ward and had meet­ings with the reg­u­la­tor to at­tempt to as­suage con­cerns and get its drug to mar­ket.

So the biotech went ahead and, in Au­gust, asked the drug reg­u­la­tor to ap­prove the treat­ment for neg­a­tive symp­toms in peo­ple with schiz­o­phre­nia.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN